7 results match your criteria: "Prof. Edgar Santos Hospital Complex[Affiliation]"
Stem Cells Int
November 2020
Health Science Institute, Federal University of Bahia, Salvador, BA 40110-100, Brazil.
The potential use of bone marrow mesenchymal stromal cells (BM-MSCs) for the treatment of osteonecrosis in sickle cell disease (SCD) patients is increasing. However, convenient BM-MSC quantification and functional property assays are critical factors for cell-based therapies yet to be optimized. This study was designed to quantify the MSC population in bone marrow (BM) samples from SCD patients with osteonecrosis (SCD group) and patients with osteoarticular complications not related to SCD (NS group), using flow cytometry for CD271CD45 cell phenotype and CFU-F assay.
View Article and Find Full Text PDFMediators Inflamm
October 2021
Health Science Institute, Federal University of Bahia, Salvador, BA 40110-100, Brazil.
Recent evidence suggests that abnormalities involving CD4T lymphocytes are associated with the pathophysiology of osteonecrosis (ON); however, few studies have addressed the CD4T cells in ON related to sickle cell disease (SCD/ON). In addition, T cells producing multiple cytokines simultaneously are often present in the inflammatory milieu and may be implicated in the immune response observed in SCD/ON. In the present study, we aimed to characterize the functional status of CD4T cells in SCD by simultaneously determining the frequency of IFN- , IL-4, and IL-17 CD4T in cell cultures under exogenous stimuli.
View Article and Find Full Text PDFBMC Musculoskelet Disord
May 2018
Health Science Institute, Federal University of Bahia, Av. Reitor Miguel Calmon, s/n, Vale do Canela, Salvador, BA, 40110-100, Brazil.
Background: The purpose of our study was to evaluate safety, feasibility and clinical results of bone marrow mononuclear cell (BMC) implantation for early-stage osteonecrosis of the knee (OK) secondary to sickle cell disease.
Methods: Thirty-three SCD patients (45 knees) with OK treated with BMC implantation in the osteonecrotic lesion were clinically and functionally evaluated through the American Knee Society Clinical Score (KSS), Knee Functional Score (KFS) and Numeric Rating Scale (NRS) pain score. MRI and radiographic examinations of the knee were assessed during a period of five years after intervention.
Int Orthop
July 2018
Health Science Institute, Federal University of Bahia, Av. Reitor Miguel Calmon, s/n, Vale do Canela, Salvador, BA, 40110-100, Brazil.
Purpose: The aim of this study was to describe the clinical features of osteonecrosis (ON) in sickle cell disease (SCD) patients in Bahia, a Northeast state with the highest prevalence of the disease in Brazil.
Methods: Between 2006 and 2017, 283 cases of osteonecrosis in SCD patients were enrolled to analyse the age at diagnosis, genotype, gender, pain, distribution of the lesions and disease staging. MRI and radiograph were obtained at the participation.
Br J Haematol
December 2016
Petrópolis School of Medicine/Arthur de Sá Earp Faculties, Petrópolis, RJ, Brazil.
Recurrent chronic leg ulcers are among the most severe vasculopathic complications of sickle cell disease (SCD). Their treatment remains a challenge. Stem cell therapy with bone marrow mononuclear cells (BMMC) is a promising new therapeutic option for other forms of chronic ulcers.
View Article and Find Full Text PDFStem Cell Res Ther
May 2015
Petrópolis School of Medicine/Arthur de Sá Earp Faculties, Petrópolis, RJ, 25680-120, Brazil.
Introduction: Stem cell therapy with bone marrow-derived mononuclear cells (BMMCs) is an option for improving joint function in osteonecrosis of the femoral head (ONFH). Bone marrow-derived mesenchymal stromal cell (MSC) numbers and their osteogenic differentiation are decreased in patients with ONFH. However, whether this decrease also extends to the early stages of ONFH in sickle cell disease (SCD) is still unclear.
View Article and Find Full Text PDFAn Bras Dermatol
June 2014
Federal University of Bahia, Prof. Edgar Santos Hospital Complex, Salvador, BA, Brazil.